Investors
Company Overview
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid and oncological diagnostics and therapeutics. AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.
The company’s subsidiary, Sapphire Biotech, Inc., is conducting research to understand the potential of its lead drug candidate, SPX-1009, to block the spread of tumor metastasis. Additionally, Sapphire’s proprietary diagnostic tool is being used to study the company’s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.
Investor Presentation
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
SAN DIEGO, August 5, 2020 -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development, patent filing and Emergency...
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests SAN DIEGO – July 23, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare...
AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O’Rourke to Company’s Board of Directors
SAN DIEGO, July 21, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has welcomed Former...
